Lupin Limited

Lupin Limited announced that its Operations and Finance Committee has allotted 30967 fully paid-up equity shares of Rs 2 each, increasing the company's issued and paid-up share capital to Rs 91,45,31,722 consisting of 45,72,65,861 equity shares of Rs 2 each, following the exercise of vested options under the company's stock option plans for employees and its subsidiaries.

Lupin Limited disclosed the demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, on August 17, 2026, in the U.S.A., according to a filing with the National Stock Exchange of India Limited and BSE Limited.

Lupin Ltd fell for a fifth straight session today. The stock is quoting at Rs 2268.1, down 1.39% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.54% on the day, quoting at 24450. The Sensex is at 78127.11, down 0.53%.Lupin Ltd has lost around 9.01% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has increased around 3.64% in last one month and is currently quoting at 26479.55, up 0.37% on the day. The volume in the stock stood at 7.94 lakh shares today, compared to the daily average of 11.47 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 2272.4, down 0.23% on the day. Lupin Ltd jumped 16.68% in last one year as compared to a 0.15% slide in NIFTY and a 22.17% spurt in the Nifty Pharma index.The PE of the stock is 15.71 based on TTM earnings ending June 26.

Lupin Limited announced it received approval from the U.S. Food and Drug Administration under the Federal Food, Drug, and Cosmetic Act for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes, which is bioequivalent to Hoffman-LaRoche, Inc.’s Valium® Injection, and indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety; the product had estimated annual sales of USD 77.9 million in the U.S. (IQVIA MAT May 2026).

Lupin Limited announced the launch of Sugammadex Injection, 200 mg/2 mL and 500 mg/5 mL single-dose vial in the United States following approval from the United States Food and Drug Administration, with the product being bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC.

Lupin will hold a meeting of the Board of Directors of the Company on 6 August 2026.

Lupin announced the strategic spin-out of two oncology programs - LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary, Lupin Inc., into Kaveri Therapeutics Inc. (Kaveri), a U.S. based clinical-stage oncology company. Kaveri will advance these programs through global clinical trials. Under the terms of the agreement, Lupin Inc. will have a significant equity stake in Kaveri, provide seed funding, and grant them exclusive rights to the programs. Kaveri will operate as an independent entity under the leadership of Chief Executive Officer Kristi Jones, a seasoned biopharmaceutical leader with a strong track record of building and advancing innovative companies, and Chief Medical Officer Dr. Robert Pierce, who brings deep clinical expertise and will lead the company's clinical development strategy. Kaveri will seek to raise additional capital to fund its clinical development efforts. Notably, both programs have demonstrated encouraging clinical progress, with LNP7457 (PRMT5) and LNP8701 (SOS1) each reporting positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively.

Lupin announced that the 44th Annual General Meeting(AGM) of the company will be held on 4 August 2026.

Lupin has allotted 2,358 equity shares under ESOP on 08 July 2026. With this allotment, the paid up equity share capital has increased to Rs 91,44,69,788 consisting of 45,72,34,894 equity shares of Rs 2/- each.

Lupin has fixed 17 July 2026 as record date for final dividend of Rs 18 per equity share for FY 2026.